Home
Data
Calendar
Blog
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Common Stock Value | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Weighted Average Number Of Diluted Shares Outstanding | 125.32 | NA | NA | NA | 56.36 | |
| Weighted Average Number Of Shares Outstanding Basic | 125.32 | NA | 90.67 | 79.04 | 56.36 | |
| Earnings Per Share Basic | -0.67 | -0.33 | -0.47 | -0.37 | -0.18 | |
| Earnings Per Share Diluted | -0.67 | -0.33 | -0.47 | -0.37 | -0.18 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Revenue From Contract With Customer Excluding Assessed Tax | 0.19 | -0.67 | 0.00 | 0.00 | 10.66 | |
| Revenues | 0.19 | -0.67 | 0.00 | 0.00 | 10.66 | |
| Operating Expenses | 21.28 | 20.34 | 15.49 | 17.18 | 21.52 | |
| Research And Development Expense | 12.22 | 15.30 | 10.79 | 11.88 | 15.94 | |
| General And Administrative Expense | 9.07 | 5.04 | 4.71 | 5.29 | 5.58 | |
| Operating Income Loss | -21.09 | -21.01 | -15.49 | -17.18 | -10.86 | |
| Interest Income Expense Nonoperating Net | 0.59 | 0.35 | 0.39 | 0.41 | 0.22 | |
| Allocated Share Based Compensation Expense | 2.38 | 1.63 | 1.84 | 1.84 | 2.06 | |
| Profit Loss | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 | |
| Net Income Loss | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 | |
| Comprehensive Income Net Of Tax | -83.94 | -37.68 | -42.37 | -29.58 | -10.19 | |
| Net Income Loss Available To Common Stockholders Basic | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 | |
| Net Income Loss Available To Common Stockholders Diluted | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Assets | 151.23 | 54.83 | 45.20 | 43.65 | 30.00 | |
| Liabilities | 83.94 | 71.98 | 56.24 | 47.98 | 34.08 | |
| Liabilities And Stockholders Equity | 151.23 | 54.83 | 45.20 | 43.65 | 30.00 | |
| Stockholders Equity | 67.29 | -17.15 | -11.04 | -4.33 | -4.07 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Assets Current | 150.91 | 54.39 | 44.49 | 42.82 | 29.06 | |
| Cash And Cash Equivalents At Carrying Value | 146.48 | 49.90 | 37.46 | 35.62 | 22.92 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 146.48 | 49.90 | 37.46 | 35.62 | 22.92 | |
| Other Assets Current | 0.35 | 0.10 | 0.84 | 0.54 | 0.55 | |
| Prepaid Expense And Other Assets Current | 4.17 | 4.23 | 7.03 | 7.21 | 6.15 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Liabilities Current | 83.91 | 71.18 | 55.50 | 47.19 | 33.25 | |
| Accounts Payable Current | 4.02 | 1.74 | 6.00 | 4.69 | 5.55 | |
| Other Liabilities Current | 1.39 | 0.38 | 0.40 | 0.46 | 0.41 | |
| Contract With Customer Liability Current | 0.48 | 0.67 | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Liabilities Noncurrent | 0.04 | 0.80 | 0.73 | 0.79 | 0.82 | |
| Operating Lease Liability Noncurrent | 0.04 | 0.04 | 0.04 | 0.17 | 0.29 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Stockholders Equity | 67.29 | -17.15 | -11.04 | -4.33 | -4.07 | |
| Common Stock Value | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Additional Paid In Capital | 619.81 | 451.43 | 419.86 | 384.20 | 354.88 | |
| Retained Earnings Accumulated Deficit | -552.52 | -468.59 | -430.91 | -388.54 | -358.96 | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2.38 | NA | 1.84 | 1.84 | 2.06 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -18.91 | -17.00 | -14.73 | -16.45 | -6.99 | |
| Net Cash Provided By Used In Investing Activities | NA | 0.00 | 0.00 | 0.00 | 13.87 | |
| Net Cash Provided By Used In Financing Activities | 115.50 | 29.45 | 16.57 | 29.15 | -0.62 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -18.91 | -17.00 | -14.73 | -16.45 | -6.99 | |
| Net Income Loss | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 | |
| Profit Loss | -83.94 | -37.68 | -42.37 | -29.58 | -10.14 | |
| Increase Decrease In Accounts Payable | 0.53 | -4.26 | 1.32 | -0.87 | 1.02 | |
| Share Based Compensation | 2.38 | 1.63 | 1.84 | 1.84 | 2.06 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Investing Activities | NA | 0.00 | 0.00 | 0.00 | 13.87 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | 115.50 | 29.45 | 16.57 | 29.15 | -0.62 |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | ||
|---|---|---|---|---|---|---|
| Revenues | 0.19 | -0.67 | 0.00 | 0.00 | 10.66 | |
| Advanz Pharma, Research And Development Services, License And Supply Agreement | 0.20 | NA | NA | NA | NA | |
| Research And Development Services | 0.19 | NA | NA | NA | NA | |
| Revenue From Contract With Customer Excluding Assessed Tax | 0.19 | -0.67 | 0.00 | 0.00 | 10.66 | |
| Advanz Pharma, Research And Development Services, License And Supply Agreement | 0.20 | NA | NA | NA | NA | |
| Research And Development Services | 0.19 | NA | NA | NA | NA |
